Claro Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Claro Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-30	Closed	-$5K	–	567
2018 Q4	$5K	Buy	+30	New	+$4.45K	﹤0.01%	786

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Claro Advisors's JAZZ Position: Q1 2019 in Review

Claro Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 30 shares — an estimated $5K sold.

Claro Advisors first reported a position in JAZZ in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

Claro Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 30 Jazz Pharmaceuticals shares in Q1 2019, an estimated $5K.
Claro Advisors first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Claro Advisors's Jazz Pharmaceuticals position peaked at $5K in Q4 2018.
427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.